FY2029 Earnings Estimate for ACRS Issued By Leerink Partnrs

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the biotechnology company will post earnings of ($1.02) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.86) per share.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The firm had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%.

A number of other research analysts also recently weighed in on the company. Cantor Fitzgerald upgraded Aclaris Therapeutics to a “strong-buy” rating in a report on Thursday, January 30th. Leerink Partners upgraded shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. Piper Sandler upgraded Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $3.00 to $13.00 in a research note on Monday, November 18th. Finally, Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.00.

Aclaris Therapeutics Stock Performance

Shares of NASDAQ:ACRS opened at $2.57 on Thursday. The firm has a 50 day simple moving average of $2.90 and a 200 day simple moving average of $2.04. Aclaris Therapeutics has a 52 week low of $0.95 and a 52 week high of $5.17. The company has a market cap of $183.58 million, a PE ratio of -4.94 and a beta of 0.50.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ACRS. Peapod Lane Capital LLC bought a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $1,003,000. Assenagon Asset Management S.A. lifted its position in shares of Aclaris Therapeutics by 113.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company’s stock worth $985,000 after acquiring an additional 211,585 shares during the period. Geode Capital Management LLC grew its holdings in shares of Aclaris Therapeutics by 9.3% during the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock worth $974,000 after purchasing an additional 72,309 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Aclaris Therapeutics during the third quarter valued at approximately $1,053,000. Finally, Stonepine Capital Management LLC lifted its position in Aclaris Therapeutics by 27.6% in the third quarter. Stonepine Capital Management LLC now owns 2,458,873 shares of the biotechnology company’s stock worth $2,828,000 after purchasing an additional 531,427 shares during the period. Institutional investors own 98.34% of the company’s stock.

Insider Activity at Aclaris Therapeutics

In other Aclaris Therapeutics news, Director Anand Mehra bought 666,666 shares of the stock in a transaction on Tuesday, November 19th. The shares were purchased at an average price of $2.25 per share, with a total value of $1,499,998.50. Following the acquisition, the director now directly owns 710,030 shares of the company’s stock, valued at $1,597,567.50. This represents a 1,537.37 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 6.40% of the stock is currently owned by company insiders.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.